Skip to main content

Table 4 Unadjusted and adjusted hazard ratios related to hospitalizations according to IgG subclass levels in the MACRO and STATCOPE cohorts

From: Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD

MACRO – Time to first Hospitalization
IgGa Univariate analysis Multivariate analysisb
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
IgG1 1.51 (1.16–1.99) 0.003 1.52 (1.15–2.02) 0.004
IgG2 1.37 (1.12–1.67) 0.002 1.33 (1.08–1.64) 0.007
IgG3 1.03 (0.85–1.24) 0.79 1.01 (0.84–1.44) 0.90
IgG4 1.01 (0.89–1.12) 0.99 1.00 (0.88–1.12) 0.94
STATCOPE – Time to first Hospitalization
IgGa Univariate analysis Multivariate analysisb
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
IgG1 1.33 (0.98–1.80) 0.07 1.27 (0.91–1.76) 0.16
IgG2 1.39 (1.11–1.74) 0.004 1.43 (1.12–1.83) 0.004
IgG3 0.97 (0.79–1.19) 0.75 0.90 (0.73–1.12) 0.36
IgG4 1.08 (0.95–1.22) 0.22 1.06 (0.93–1.20) 0.39
  1. aIgG subclass levels expressed using a negative-log transformation (base 2), with one-unit increase on this log scale being equivalent to a 50% decrease of IgG subclass levels. bAdjusted hazard ratios for IgG levels were calculated using a Cox Proportional Hazards model with adjustments for the following covariates: study drug (azithromycin vs. placebo in MACRO - First cohort; simvastatin vs. placebo in STATCOPE - Replication cohort), age, gender, ethnicity (Caucasian vs. Non-Caucasian), FEV1 (% of predicted values), smoking status (current vs. former smokers), oxygen dependence, inhaled corticosteroid use, and treatment with systemic steroids in previous year. Legend: 95% CI = 95% Confidence Interval